Title for MeetingAbstracts
Alphabetical listing of titles
-
Activities of Cell Wall Inhibitors Towards Vancomycin-Resistant Staphylococcus aureus (VRSA) Isolated at the Hershey Medical Center.
-
Activities of clarithromycin, azithromycin and ofloxacin in combination with liposomal or unencapsulated GM-CSF against intramacrophage mycobacterium avium-M. intracellulare.
-
Activities of Combinations of New Fluoroquinolones or Clarithromycin with Other Drugs against Extracellular and Intramacrophagial Mycobacteria.
-
Activities of GAR-936 Alone and in Combination Versus Multi-Drug Resistant Staphylococcus aureus and Enterococcus faecium.
-
Activities of New Macrolides and New Fluoroquinolones against Mycobacterium ulcerans Infection in Mice.
-
Activities of Non-Fluorinated Quinolones Against Recent Clinical Isolates of Gram-Positive Cocci, Including Those Resistant to Currently Available Fluoroquinolones.
-
Activities of Respiratory Fluoroquinolones against Penicillin-Resistant S. pneumoniae Isolated in Six European Countries in 2000-01.
-
Activities of Rifalazil Alone and in Combination with Gatifloxacin in a Mouse Model of Mycobacterium kansasii Infection.
-
Activities of TAK-187 against Drug-Resistant Strains of the Protozoan Parasite Trypanosoma cruzi.
-
Activities of the AIDS hotline in Rosario City, Argentina.
-
Activities of The Jordan Red Crescent.
-
Activities of United Nations volunteers supporting people living with HIV/AIDS.
-
Activities of Voriconazole (VOR), Posaconazole (POS) and Fluconazole (FLU) against 3,932 Candida Species and 237 Cryptococcus neoformans: Report from the ARTEMIS Global Antifungal Surveillance Program, 2001-2002.
-
Activities of WCK 771A and WCK 919, Two Experimental Quinolones, Compared with Five Other Quinolones against Quinolone Susceptible and Resistant Staphylococci.
-
Activities of Wednesday Friends' Club (an organization in Thailand supports PWA).
-
Activities/programmes addressing support for children and young people - an organization's focus.
-
Activities/Programmes addressing support for children and young people.
-
Activities/programs reducing impact on households and extended families.
-
Activity and Diffusion of GAR 936 (GAR) in Experimental Enterococcal Endocarditis.
-
Activity and in vitro immunotoxicity of BCH 189 a novel anti-HIV nucleoside analogue.
-
Activity and Spectrum Evaluation of Dalbavancin (V-glycopeptide and BI397), A Novel ``Glycopeptide Class Antimicrobial.
-
Activity and Spectrum of BMS 284756 (BMS) Tested Against 3546 Strains of Ciprofloxacin-Resistant Gram-Positive Cocci.
-
Activity In Vitro of Ravuconazole (RVZ) against Spanish Clinical Isolates of Yeasts and Filamentous Fungi.
-
Activity of 22 different anti-Mycobacterium avium regimens and selection of mutants in the beige mouse model.
-
Activity of 8-aminoquinolines and their metabolites against Pneumocystis carinii of rat origin.
-
Activity of a new antifungal voriconazole against Candida spp.
-
Activity of a new formulation of saquinavir in combination with two nucleosides in treatment naive patients.
-
Activity of a New Ketolide ABT-773 In Vitro against S. pneumoniae Non-Susceptible to Penicillin or Macrolides.
-
Activity of a New Triazole Antifungal, BMS 207147, against Clinical Isolates of the Endemic Mycoses, and Comparison with Itraconazole (IZ) and Fluconazole (FZ).
-
ACTIVITY OF A NOVEL ANTI-HIV PROTEASE INHIBITOR AGAINST VIRAL STRAINS RESISTANT TO COMMERCIALLY-AVAILABLE DRUGS.